ClinicalTrials.gg
RecruitingNCT06392633Updated Apr 30, 2024

SURGERY VS BOTULINUM TOXIN ON QUALITY OF LIFE IN STROKE PATIENTS: RANDOMIZED TRIAL

An interventional study of spastic hand sugery and Botulinum Toxin A in Stroke, sponsored by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-30.

Sponsored by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Registered 3 years 3 months after the study started (first participant enrolled Jan 2021, registered Apr 2024).
  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 323 studies in Stroke with a site in Spain — 73 open to participants now, 91 under way, 6 of them phase 3. Stroke · Spain.

Planned enrollment
158th of 246
44 · median 70
Started
2021
with 21 others
No phase
159 of 323
50 open now
Primary completion
2024-06
later than 9 of 90 live
Registered
262nd of 323
by date

Among the 323 studies in Stroke with a site in Spain, this one is the 158th largest by planned enrollment of the 246 interventional ones that give a count, is one of 22 that started in 2021, is one of 159 with no phase, reaches primary completion later than 9 of the 90 other live ones, and was the 262nd registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

73 of the 323 studies in Stroke with a site in Spain are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 323 studies in Stroke with a site in Spain, or all of them as a file.
02

Study summary

We present a research project in the form of a controlled clinical trial with the aim of analyzing and demonstrating whether the surgical treatment of upper limb spasticity is an effective and efficient measure to improve dependence and quality of life perceived by patients with sequelae of stroke and therefore, should be included in the therapeutic protocols, in which it is not usually contemplated, as a complement or alternative to traditional treatment with botulinum toxin, rehabilitation and occupational therapy.

Read the detailed description

Cerebrovascular accident (CVA) or "stroke" is the leading cause of permanent disability in adulthood and many patients require lifelong medical treatment and assistance from other people for the development of their daily activities. The repercussion in the family, professional, labor and social fields is enormous, producing a very important economic expense. The usual treatment of spastic upper limb secondary to stroke is rehabilitation, occupational therapy and periodic injection of botulinum toxin, and surgical correction is not usually considered. A two-arm Randomized Clinical Trial [surgical treatment (n=22) vs. botulinum toxin (n=22)] is proposed with the aim of investigating the efficacy and efficiency of surgery for upper limb spasticity with respect to treatment with botulinum toxin in patients with established spastic sequelae after stroke.

We will evaluate the effect on functionality and "hygienic" changes; the impact on quality of life, sleep quality, anxiety and depression; as well as on brain activity by Functional Magnetic Resonance Imaging, at baseline and at 6 and 12 months follow-up. The health and care costs of the established groups of patients will also be evaluated. This research is framed in the context of chronic diseases, aging and patients with functional and mobility difficulties. The results of this work are expected to have a great impact due to the high prevalence of the disease, the severe disability it causes, and the number of patients who would benefit, in addition to the savings in healthcare resources. The incorporation of surgery into stroke care would change the current treatment paradigm, favoring the formation of multidisciplinary teams for the treatment of the disease.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • spastic hand
  • botulinum toxin
  • surgery
  • quality of life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of legal age, with spasticity in the upper limb due to stroke, with a minimum evolution time of 12 months, who, after being informed orally and in writing of the objectives of the study, sign the form (themselves or their legal representatives).

Exclusion criteria

Exclusion Criteria:

  • Absence of consent, refusal of possible surgical treatment, stroke evolution time of less than 12 months, anaesthetic risk (ASA) class IV or higher, presence of involuntary movements, inability to respond adequately to surveys, deformities that cannot be addressed by surgical treatment or inability to follow up for at least one year.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Active comparator
    Group I

    Patients who meet the inclusion criteria and who will be treated with botulinum toxin (1 injection/4months).

    Drug: Botulinum Toxin A

  • Experimental
    Group II

    Patients who meet the inclusion criteria and who will be treated by surgery.

    Procedure: spastic hand sugery

Interventions

  • Procedurespastic hand sugery

    Deformity correction can be performed with single event multilevel surgery, using a combination of soft tissue releases and lengthening, tendon transfers and joint stabilization procedures. In addition, selective and supraselective neurectomies can also be performed.

  • DrugBotulinum toxin type AStudies of Botulinum toxin type ABotulinum toxin type A pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Treatment consists of periodic injections of the toxin into the spastic muscles. It causes reversible chemical denervation by preventing the release of acetylcholine vesicles at the neuromuscular junctions of the affected muscles.

06

What researchers measure

Primary outcomes

  1. Quality of life by 36-Item Short Form Survey Instrument (SF-36)

    SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and have been widely used.

    Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)

  2. Quality of life by Newcastle Stroke-Specific Quality of Life Measure

    is a specific questionnaire to measure the QoL of patients who suffered a stroke. It was developed and validated by Buck et al. It is different from other questionnaires because it includes domains of vision, cognition and communication, and it can used for patients with ischaemic or haemorrhagic stroke and motor aphasia.

    Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)

Secondary outcomes

  1. Functional outcome by Asworth scale

    It measures the degree of spasticity from 0 to 5. Significant improvement of at least 1 of the 5 joints evaluated (elbow, forearm, wrist, thumb, fingers) will be considered a positive result.

    Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)

  2. Functional outcome by House hand function scale

    Scale of hand function with 10 degrees of capability

    Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)

  3. Functional outcome by Fugl-mayer scale

    is the first quantitative evaluative instrument for measuring sensorimotor stroke recovery, based on Twitchell and Brunnstrom's concept of sequential stages of motor return in the hemiplegic stroke patient.

    Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)

  4. Functional outcome by GAS score

    5-grade scale for the domains hygiene, esthetics and pain. Krasny-Pacini y cols, 2013

    Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)

  5. Carer Burden by Carer Burden Score

    Scores the caregiver's degree of difficulty for 4 basic activities (nail clipping, palm grooming, armpit grooming, arm dressing) on a 5-point Likert scale.

    Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)

  6. Pain by Visual Analogue Scale

    A tool used to help a person assess the intensity of certain sensations and feelings, such as pain. The visual analogue pain scale is a straight line where one end means no pain and the other end means the worst pain imaginable. The patient marks a point on the line that matches the amount of pain he or she feels.

    Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)

  7. Sleep health by SATED scale

    5 questions scale about satisfaction, alertness, timing, efficiency and duration of sleep to know the sleep health of patients. Higher scores (0-10) mean better sleep health.

    Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)

  8. Anxiety and depression by HADS scale

    Includes 14 items, with scores from 0 to 3 (higher scores reflect greater severity of symptomatology).

    Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)

  9. Activity, structure and brain function by MRI

    Functional Magnetic Resonance Imaging (fMRI) at rest and with the patient's repeated attempt to extend the elbow and wrist. Anatomical and functional volumes shall be obtained by MRI and fMRI imaging, using a Siemens Prisma 3T functional MRI.

    Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Jun 2024, 41 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 41 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2024
First posted
Apr 30, 2024
StartActual
Jan 1, 2021
Primary completionEst.
Jun 1, 2024
CompletionEst.
Dec 1, 2024
Last update
Apr 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06392633
Lead sponsor
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Responsible party
Pedro Hernández Cortés (MD PhD, Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental) — Principal investigator
First posted
Apr 30, 2024
Start date
Jan 1, 2021
Primary completion
Jun 1, 2024 (estimated)
Completion
Dec 1, 2024 (estimated)
Last update
Apr 30, 2024

Study contacts

Pedro Hernández-Cortés, MD PhD
Contact
phc@ugr.es
958240721

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion